

Maria Teresa Pellecchia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5371334/publications.pdf>

Version: 2024-02-01

159
papers

6,966
citations

53794

45
h-index

76900

74
g-index

160
all docs

160
docs citations

160
times ranked

7644
citing authors

#	ARTICLE	IF	CITATIONS
1	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , 2013, 12, 264-274.	10.2	426
2	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 781-787.	2.2	226
3	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
4	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	3.9	215
5	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	3.9	205
6	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752.	2.8	197
7	The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. <i>Brain</i> , 2005, 128, 1855-1860.	7.6	172
8	The relevance of gender in Parkinson's disease: a review. <i>Journal of Neurology</i> , 2017, 264, 1583-1607.	3.6	171
9	Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 14-17.	1.9	158
10	The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. <i>PLoS ONE</i> , 2013, 8, e70244.	2.5	150
11	A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016, 87, 1591-1598.	1.1	139
12	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186.	3.9	126
13	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129.	2.8	124
14	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1219-1226.	2.2	113
15	Unawareness of dyskinesias in Parkinson's and Huntington's diseases. <i>Neurological Sciences</i> , 2001, 22, 105-106.	1.9	105
16	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	3.9	102
17	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 489-493.	2.2	97
18	Hearing impairment in Parkinson's disease: Expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012, 27, 1530-1535.	3.9	93

#	ARTICLE	IF	CITATIONS
19	Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. <i>Lancet Neurology</i> , The, 2016, 15, 1063-1074.	10.2	86
20	Stridor in multiple system atrophy. <i>Neurology</i> , 2019, 93, 630-639.	1.1	86
21	Ropinirole as a Treatment of Restless Legs Syndrome in Patients on Chronic Hemodialysis. <i>Clinical Neuropharmacology</i> , 2004, 27, 178-181.	0.7	84
22	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.5	83
23	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1034-1038.	2.2	83
24	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855.	3.6	83
25	GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111.	3.9	83
26	Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018, 265, 2602-2613.	3.6	80
27	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005, 112, 1677-1686.	2.8	75
28	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	2.5	74
29	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014, 261, 2319-2328.	3.6	74
30	The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. <i>European Journal of Neurology</i> , 2016, 23, 1673-1679.	3.3	74
31	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016, 39, 405-412.	1.1	73
32	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
33	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	10.2	70
34	Diffusion-weighted imaging in multiple system atrophy: A comparison between clinical subtypes. <i>Movement Disorders</i> , 2009, 24, 689-696.	3.9	68
35	Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 276-281.	2.3	64
36	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 137-140.	2.2	62

#	ARTICLE	IF	CITATIONS
37	Impulsive-compulsive behaviors in <i>parkin</i>-associated Parkinson disease. <i>Neurology</i> , 2016, 87, 1436-1441.	1.1	61
38	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. <i>Journal of Neurology</i> , 2012, 259, 1808-1813.	3.6	60
39	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854.	2.2	60
40	Relationship between apathy and cognitive dysfunctions in <i>de novo</i> untreated <sc>P</sc>arkinson's disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015, 22, 253-260.	3.3	58
41	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. <i>PLoS ONE</i> , 2013, 8, e69190.	2.5	55
42	Physical therapy in Parkinson's disease: an open long-term rehabilitation trial. <i>Journal of Neurology</i> , 2004, 251, 595-598.	3.6	49
43	Reduced striatal [^{123I}]FP-CIT binding in SCA2 patients without parkinsonism. <i>Annals of Neurology</i> , 2004, 55, 426-430.	5.3	49
44	Presence and progression of non-motor symptoms in relation to uric acid in <i>de novo</i> <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 93-98.	3.3	49
45	Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. <i>Cell Death and Disease</i> , 2018, 9, 385.	6.3	48
46	Progression of striatal and extrastriatal degeneration in multiple system atrophy: A longitudinal diffusion-weighted MR study. <i>Movement Disorders</i> , 2011, 26, 1303-1309.	3.9	47
47	Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study. <i>Movement Disorders</i> , 2007, 22, 559-563.	3.9	46
48	Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. <i>Journal of Neurology</i> , 2013, 260, 438-444.	3.6	46
49	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730.	3.6	45
50	Postganglionic sudomotor denervation in patients with multiple system atrophy. <i>Neurology</i> , 2014, 82, 2223-2229.	1.1	45
51	Restless legs syndrome is a common feature of adult celiac disease. <i>Movement Disorders</i> , 2010, 25, 877-881.	3.9	44
52	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014, 35, 379-383.	1.9	42
53	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 89-92.	2.2	42
54	Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 802-807.	3.3	41

#	ARTICLE	IF	CITATIONS
55	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	3.9	41
56	Olfactory dysfunction in Parkinsonism caused by <i>PINK1</i> mutations. <i>Movement Disorders</i> , 2009, 24, 2350-2357.	3.9	39
57	Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 98-103.	1.9	39
58	Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 275-281.	2.1	38
59	PERK-Mediated Unfolded Protein Response Activation and Oxidative Stress in PARK20 Fibroblasts. <i>Frontiers in Neuroscience</i> , 2019, 13, 673.	2.8	38
60	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2112-2118.	3.6	37
61	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 1399-1402.	2.8	36
62	The Role of VPS35 in the Pathobiology of Parkinson's Disease. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 199-227.	3.3	35
63	Clinical Presentation and Treatment of Wilson's Disease: A Single-Centre Experience. <i>European Neurology</i> , 2003, 50, 48-52.	1.4	34
64	Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. <i>Molecular Brain Research</i> , 1997, 52, 307-317.	2.3	32
65	Hallervorden-Spatz syndrome resembling a typical Tourette syndrome. <i>Movement Disorders</i> , 2002, 17, 618-620.	3.9	32
66	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? <i>Parkinsonism and Related Disorders</i> , 2014, 20, 772-775.	2.2	32
67	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3588-3597.	3.8	32
68	Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. <i>Journal of Neurology</i> , 2008, 255, 1372-1377.	3.6	31
69	The language profile of progressive supranuclear palsy. <i>Cortex</i> , 2019, 115, 294-308.	2.4	31
70	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
71	Motor, cognitive and behavioral differences in MDS PSP phenotypes. <i>Journal of Neurology</i> , 2019, 266, 1727-1735.	3.6	30
72	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508.	2.5	30

#	ARTICLE	IF	CITATIONS
73	Increased bilirubin levels in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 954-959.	3.3	29
74	Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 127-131.	2.1	29
75	Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. <i>Journal of Neurology</i> , 2019, 266, 1394-1404.	3.6	29
76	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 256-259.	2.2	28
77	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 106-110.	2.2	28
78	Twenty-Four Novel Mutations in Wilson Disease Patients of Predominantly Italian Origin. <i>Genetic Testing and Molecular Biomarkers</i> , 2007, 11, 328-332.	1.7	27
79	Cognitive correlates of "pure apathy" in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 101-104.	2.2	27
80	Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. <i>Movement Disorders</i> , 2010, 25, 2621-2626.	3.9	25
81	Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. <i>Clinical Endocrinology</i> , 2005, 62, 428-433.	2.4	24
82	The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features. <i>European Journal of Neurology</i> , 2010, 17, 666-671.	3.3	24
83	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 116-119.	2.2	24
84	MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes. <i>Movement Disorders</i> , 2018, 33, 1361-1365.	3.9	24
85	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 8936.	3.3	24
86	Evolution of neuropsychological profile in motor subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 67-73.	2.2	23
87	Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale. <i>Quality of Life Research</i> , 2017, 26, 2533-2540.	3.1	22
88	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	2.5	22
89	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132.	2.2	22
90	Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). <i>Journal of the Neurological Sciences</i> , 2016, 367, 158-161.	0.6	21

#	ARTICLE	IF	CITATIONS
91	Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. <i>Neuroscience Letters</i> , 2010, 468, 287-291.	2.1	20
92	A comparison of auditory and vestibular dysfunction in Parkinson's disease and Multiple System Atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 51-57.	2.2	20
93	Quitting smoking: An early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 216-220.	2.2	19
94	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694.	1.9	18
95	Serum miR-30c-5p is a potential biomarker for multiple system atrophy. <i>Molecular Biology Reports</i> , 2019, 46, 1661-1666.	2.3	18
96	Speech disorder and vocal tremor in postural instability/gait difficulty and tremor dominant subtypes of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 1295-1304.	2.8	18
97	Neuropsychological profile of hearing-impaired patients and the effect of hearing aid on cognitive functions: an exploratory study. <i>Scientific Reports</i> , 2021, 11, 9384.	3.3	18
98	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
99	Cortical pattern of reduced perfusion in hearing loss revealed by ASL-MRI. <i>Human Brain Mapping</i> , 2019, 40, 2475-2487.	3.6	17
100	Comparing postural instability and gait disorder and akinetic-rigid subtyping of Parkinson disease and their stability over time. <i>European Journal of Neurology</i> , 2019, 26, 1212-1218.	3.3	17
101	Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. <i>Neurological Sciences</i> , 2001, 22, 79-80.	1.9	16
102	Early Ataxia and Subsequent Parkinsonism: PLA2G6 Mutations Cause a Continuum Rather Than Three Discrete Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 125-128.	1.5	16
103	Sex Differences in Parkinson's Disease: From Bench to Bedside. <i>Brain Sciences</i> , 2022, 12, 917.	2.3	16
104	Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables. <i>Neurological Sciences</i> , 2022, 43, 4803-4809.	1.9	15
105	Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK2. <i>Movement Disorders</i> , 2009, 24, 303-305.	3.9	14
106	Progressive Supranuclear Palsy-Like Phenotype in a GBA E326K Mutation Carrier. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 444-446.	1.5	14
107	Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 632891.	3.4	14
108	Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2219-2219.	3.9	14

#	ARTICLE	IF	CITATIONS
109	Growth Hormone Stimulation Tests in the Differential Diagnosis of Parkinson's Disease. <i>Clinical Medicine and Research</i> , 2006, 4, 322-325.	0.8	13
110	How does smoking affect olfaction in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014, 340, 215-217.	0.6	13
111	Excitatory and inhibitory mechanisms in Wilson's disease: investigation with magnetic motor cortex stimulation. <i>Journal of the Neurological Sciences</i> , 2001, 192, 35-40.	0.6	12
112	Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania. <i>Journal of Parkinson's Disease</i> , 2014, 4, 123-128.	2.8	12
113	Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy. <i>PLoS ONE</i> , 2019, 14, e0223621.	2.5	12
114	Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 49-55.	2.2	12
115	The arginine growth hormone stimulation test in bradykineticâ€rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194.	3.9	11
116	Validation of an Italian version of the 40â€item University of Pennsylvania Smell Identification Test that is physician administered: Our experience on one hundred and thirtyâ€eight healthy subjects. <i>Clinical Otolaryngology</i> , 2014, 39, 53-57.	1.2	11
117	Psychometric properties of the Beck Depression Inventoryâ€II in progressive supranuclear palsy. <i>Brain and Behavior</i> , 2021, 11, e2344.	2.2	11
118	Brain anatomical substrates of mirror movements in Kallmann syndrome. <i>NeuroImage</i> , 2015, 104, 52-58.	4.2	10
119	Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 103-107.	2.1	10
120	From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 272-273.	2.2	10
121	Effects of gender on cognitive and behavioral manifestations in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 925-934.	2.8	10
122	The role of disease duration and severity on novel clinical subtypes of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 31-34.	2.2	10
123	Serum uric acid is associated with apathy in early, drug-naïve Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2016, 123, 371-377.	2.8	9
124	Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy. <i>Scientific Reports</i> , 2021, 11, 21683.	3.3	9
125	Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2020, 11, 603161.	2.4	8
126	Drug induced oromandibular dystonia: A case related to prolonged use of cetirizine. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 566-567.	2.2	7

#	ARTICLE	IF	CITATIONS
127	Parkinson's disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 495-508.	2.8	7
128	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. <i>Aging and Mental Health</i> , 2021, 25, 1998-2002.	2.8	7
129	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2021, 12, 711358.	2.4	7
130	Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 781480.	3.4	7
131	Early MRI findings in acquired hepatocerebral degeneration. <i>Neurological Sciences</i> , 2013, 34, 589-591.	1.9	6
132	Pallidal stimulation in atypical pantothenate kinase-associated neurodegeneration: Six-year follow-up. <i>Movement Disorders</i> , 2014, 29, 276-277.	3.9	6
133	Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 652-662.	1.5	6
134	Long-Range Auditory Functional Connectivity in Hearing Loss and Rehabilitation. <i>Brain Connectivity</i> , 2021, 11, 483-492.	1.7	6
135	Comment on Szewczyk-Krolikowski et al.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1319-1320.	2.2	5
136	Identifying Correlations among Biomedical Data through Information Retrieval Techniques. , , .		5
137	Bipolar Disorder and Parkinson's Disease: A 123I-hoflupane Dopamine Transporter SPECT Study. <i>Frontiers in Neurology</i> , 2021, 12, 652375.	2.4	5
138	Theory of mind and joint action in Parkinson's disease. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2018, 18, 1320-1337.	2.0	4
139	Theory of Mind in multiple system atrophy: comparison with Parkinson's disease and healthy subjects. <i>Journal of Neural Transmission</i> , 2020, 127, 915-923.	2.8	4
140	The language profile in multiple system atrophy: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 1195-1203.	2.8	4
141	Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults. <i>Neurological Sciences</i> , 2022, 43, 3079-3087.	1.9	4
142	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1143-1148.	2.2	3
143	SPECT Molecular Imaging in Familial Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 142, 225-260.	2.0	3
144	Cross-modal connectivity effects in age-related hearing loss. <i>Neurobiology of Aging</i> , 2022, 111, 1-13.	3.1	3

#	ARTICLE	IF	CITATIONS
145	Evolution of mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2014, 82, 1384-1384.	1.1	2
146	On the relationship between side of onset and cognition in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1391-1392.	2.2	2
147	Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 82-90.	2.2	2
148	Energy expenditure, body composition and dietary habits in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2021, , 1.	3.6	1
149	Female sexual dysfunction in multiple system atrophy: does it matter?. <i>Clinical Autonomic Research</i> , 2021, 31, 649-650.	2.5	1
150	Uncovering clinical and radiological asymmetry in progressive supranuclear palsyâ€”Richardsonâ€™s syndrome. <i>Neurological Sciences</i> , 2022, , 1.	1.9	1
151	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1331-1331.	3.9	0
152	Is arginine test a reliable tool for differential diagnosis of multiple system atrophy?. <i>Annals of Neurology</i> , 2010, 68, 564-565.	5.3	0
153	Comment on Numao etÂal.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 680-681.	2.2	0
154	Olfaction in Homozygous and Heterozygous <sc>SYNJ</sc>1 Arg258Gln Mutation Carriers. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 413-416.	1.5	0
155	Early Cues to Detect Atypical Panthothenate Kinase-Associated Neurodegeneration. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, e78-e79.	1.8	0
156	Impulsive-compulsive behaviors in Parkin-associated Parkinson's disease: a case-control study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e26-e27.	2.2	0
157	Bilirubin and Uric Acid: Two Different Anti-oxidants in Parkinsonâ€™s Disease. <i>Cell Biochemistry and Biophysics</i> , 2016, 74, 91-92.	1.8	0
158	Adult-onset pure tic disorder after post-traumatic hypoxic lesions of the globus pallidus. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 75-76.	2.2	0
159	Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status. <i>Neurological Sciences</i> , 0, , .	1.9	0